Stereotaxis
STXS
85 hedge funds and large institutions have $67.2M invested in Stereotaxis in 2022 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 27 increasing their positions, 25 reducing their positions, and 23 closing their positions.
8% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 25
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4.87% less ownership
Funds ownership: 53.89% → 49.02% (-4.9%)
9% less funds holding
Funds holding: 93 → 85 (-8)
30% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 23
55% less capital invested
Capital invested by funds: $149M → $67.2M (-$81.4M)
Top Buyers
Top Sellers
| 1 |
PVI
Pura Vida Investments
New York
|
-$5.52M |
| 2 |
BlackRock
New York
|
-$5.48M |
| 3 |
HM
HealthCor Management
New York
|
-$3.07M |
| 4 |
RC
Roubaix Capital
Denver,
Colorado
|
-$2.52M |
| 5 |
State Street
Boston,
Massachusetts
|
-$2.43M |
STXS Hedge Fund Activity: Q2 2022 in Review
85 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Stereotaxis (STXS) for Q2 2022, worth a combined $67.2M — down 55% from $149M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of STXS and 16 opened new positions — a net loss of 7 holders — while 25 trimmed existing stakes and 27 added.
The largest buyer was Renaissance Technologies, adding an estimated $1.74M. The largest seller was Pura Vida Investments, exiting entirely with an estimated $5.52M sold.
- 85 institutional investors held Stereotaxis (STXS) as of Q2 2022, down from 93 in Q1 2022.
- Funds reported $67.2M of Stereotaxis stock for Q2 2022, down 55% quarter-over-quarter.
- 16 funds opened new Stereotaxis positions in Q2 2022 and 23 closed out, a net change of -7 holders.
- The largest Stereotaxis buyer in Q2 2022 was Renaissance Technologies, an estimated $1.74M added.
- The largest Stereotaxis seller in Q2 2022 was Pura Vida Investments, an estimated $5.52M sold.
Based on aggregated 13F filings for Q2 2022.